Insider transactions

Baker Brothers Life Sciences Capital (GP), LLC

CIK 1307729 · last filed 2012-02-23

Baker Brothers Life Sciences Capital (GP), LLC is a corporate insider who has filed 62 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing shows the insider bought $9.6M of GHDX on Feb 23, 2012. Across all open-market trades the lifetime net is +$533.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.50B across reported positions. The firm reports its address in New York, NY. 244 SEC filings were submitted jointly with Julian Baker.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.50B
Companies
14
Total Filings
62
Lifetime Open-Market Net
$533.25M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

INCY price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
667 MADISON AVENUE
21ST FLOOR
NEW YORK, NY 10065
Phone
(212) 339-5600
State of Incorporation
DE
Formerly Known As
Baker Biotech Capital III (GP), LLC (2005–2006)
Related Filers
Julian Baker — 244 joint filings, latest 2012-03-14
Felix Baker — 228 joint filings, latest 2012-03-14
INCYTE CORP — 29 joint filings, latest 2012-01-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GENOMIC HEALTH INC (GHDX) Delisted Director 7,639,436 — — $173.92M 11 2012-02-23
Ardea Biosciences, Inc./DE (RDEA) Delisted Director 4,922,226 — — $44.72M 1 2012-02-03
INCY Director 12,213,272 $113.31 $1.38B $232.64M 16 2012-01-17
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 5,077,676 — — $0 1 2012-01-09
VIROPHARMA INC (VPHM) Delisted 10%+ Owner 8,011,759 — — $51.49M 5 2011-08-25
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted 10%+ Owner 6,112,357 — — $0 1 2011-07-05
BCRX 10%+ Owner 3,841,124 $7.88 $30.27M $0 1 2011-07-05
Seagen Inc. (SGEN) Delisted Director 11,119,820 $228.74 $2.54B -$16.96M 4 2010-05-27
RPRX 10%+ Owner 1,345,866 $64.76 $87.16M $1.78M 1 2010-04-28
Aceragen, Inc. (IDRA) Delisted 10%+ Owner 3,218 $7.22 $23.3K -$8.70M 6 2008-07-30
ALLOS THERAPEUTICS INC (ALTH) Delisted 10%+ Owner 8,002,776 — — $63.07M 3 2008-05-27
NEUROGEN CORP (NRGN) Delisted Director — — — $0 1 2008-04-15
TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted 10%+ Owner 1,821,429 — — -$7.7K 1 2008-04-08
Aceragen, Inc. (IDP) Delisted 10%+ Owner 1,004,905 — — -$8.69M 6 2007-12-07

Recent Filings

62 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2012-02-23 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +343,554 $9.64M EDGAR
2012-02-10 GENOMIC HEALTH INC (GHDX) Delisted Buy (P) +1,253,745 $33.05M EDGAR
2012-02-03 Ardea Biosciences, Inc./DE (RDEA) Delisted Buy (P) +2,630,484 $44.72M EDGAR
2012-01-26 — Buy (P) +1,501,956 $27.17M
2012-01-17 INCY Buy (P) +1,629,717 $26.68M EDGAR
2012-01-09 SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Grant (A) +3,231,675 $81.37M EDGAR
2012-01-03 — U −20,008,014 -$85.03M
2011-12-12 INCY Buy (P) +1,210,563 $16.18M EDGAR
2011-12-06 — Buy (P) +264,591 $4.08M
2011-12-01 INCY Buy (P) +7,218,537 $94.76M EDGAR
Showing 1–10 of 62
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.